f3-Lactamase inhibitors such as sulbactam are (3-lactam compounds that have low antimicrobial activity but are able to inhibit enzymes (/3-lactamases) that destroy j3-lactam antibiotics like penicillins and cephalosporins. The main activity of 33-lactamase inhibitors is directed against plasmidmediated transferable enzymes and various extended-spectrum enzymes. Sulbactam is also active against some of the fixed chromosomally mediated enzymes produced by gram-negative bacteria and is active against Bacteroides and Acinetobacter species. Cefoperazone, a third-generation cephalosporin, is active against a wide range of gram-positive and gram-negative bacteria, including Enterobacteriaceae and Pseudomonas species. However, transferable f3 Aactamases are now produced by numerous gram-negative organisms, mitigating the effectiveness of therapy with this agent. Chromosomally mediated enzymes are less common but can be induced in some strains of Klebsiella, Enterobacter, and Serratia species. The full potential of cefoperazone against Enterobacteriaceae and Pseudomonas species is restored by the addition of sulbactam; this addition extends cefoperazone's spectrum of activity to include Bacteroides and Acinetobacter species.
Bacteria have acquired a variety of mechanisms to resist the action of antibiotics. The production of ,8-lactamases, enzymes that destroy penicillins and cephalosporins by hydrolyzing their /3-lactam nucleus, is the most common mechanism of resistance. A wide variety of 0-lactamases have been described [1] . Transferable /3-lactamases, the most widespread enzymes in this class, are produced by many bacterial species. Of particular importance with regard to cephalosporin use are the chromosomally mediated enzymes produced at high levels by Enterobacter, Serratia, and several other species. However, at this time, the major resistance mechanisms arise via plasmids rather than the chromosomes of bacterial cells.
Plasmids are especially troublesome, because they are capable of transferring resistance from one organism to another. Such transferable enzymes are now rampant among the gramnegative organisms including the Enterobacteriaceae, Pseudomonas species, and fastidious gram-negative organisms such as Haemophilus influenzae and Neisseria gonorrhoeae. The most recently recognized transferable enzymes, the so-called extended-spectrum /3-lactamases, are capable of inactivating monocyclic /3-lactams and third-generation cephalosporins [2] . A further problem with respect to /3-lactam antibiotics is the class C enzymes, mainly cephalosporinases, that can be induced or selected during therapy and produce enzymes at high levels. The class C enzymes are mainly found in Enterobacter, Citrobacter, Pseudomonas, Serratia, and Morganella isolates.
Although 0-lactam resistance is a problem worldwide, the rate of resistance among bacterial species can vary widely both between and within countries. In most areas, virtually all strains of Staphylococcus aureus now produce /3-lactamase. Among the Enterobacteriaceae, transferable /3-lactamases occur in most Klebsiella strains and in 30%-50% of Escherichia coli strains isolated in hospitals of the United Kingdom. Only 5%-10% of Pseudomonas strains in the United Kingdom produce transferable /3-lactamase; however, in France the rate is higher. While substantially less common, chromosomally mediated enzymes can be a problem in some strains of Klebsiella, Pseudomonas, Enterobacter, and Serratia species [3] [4] .
The Concept of (3-Lactamase Inhibition
Past attempts to counter f3-lactam resistance centered on designing new cephalosporins that were more stable to enzymatic hydrolysis. However, experience has shown that bacteria soon produce new 0-lactamases capable of destroying the more stable drugs. A more recent (and perhaps more fundamental) approach is to combine a /3-lactamase inhibitor with a familiar f3-lactam antibiotic in an attempt to restore full therapeutic potential.
0-lactamase inhibitors are actually f3-lactam compounds with limited antimicrobial activity. Their major value is an inherent ability to limit the destructive action of /3-lactamases against more active 0-lactam compounds such as penicillins and cephalosporins. Three /3-lactamase inhibitors are currently available and include clavulanic acid and sulbactam, which were described in the 1970s, and tazobactam, a derivative of sulbactam, which was described in the early 1980s. The major on PBP2 should result in more-rapid bactericidal activity when this agent is combined with 0-lactam antibiotics [6] .
Rationale for Combining Sulbactam with Cefoperazone
Unlike the first series of cephalosporins, cefoperazone is comparatively stable in the presence of some 0-lactamases produced by enterobacteria. Its wide spectrum of activity includes gram-negative aerobes and gram-negative anaerobes. Cefoperazone is one of the few cephalosporins that possesses useful activity against Pseudomonas aeruginosa. Nevertheless, the rapid spread of f3-lactamases has compromised the full potential of cefoperazone against some of the organisms that would normally be susceptible.
Inhibition Yes

Yes
No* Not inhibiting activity of the ,13-lactamase inhibitors is directed against plasmid-mediated transferable enzymes, including TEM-1, TEM-2, SHV-1, and OXA. The /3-lactamase inhibitors also inhibit the various extended-spectrum enzymes derived from TEM and SHV enzymes that have appeared in recent years. When combined with 0-lactam antibiotics, all of these inhibitors have been shown to produce a synergistic effect against (3-lactamase -producing bacterial strains [5] .
Characteristics of Sulbactam
Sulbactam is a potent, highly specific inhibitor of a wide variety of /3-lactamases produced by common gram-positive and gram-negative aerobes and anaerobes. By forming a protein complex with 0-lactamases, sulbactam irreversibly blocks their destructive hydrolytic activity. Table 1 depicts the spectrum of sulbactam's activity against /3-lactamases produced by common pathogens. As can be seen, the drug possesses a broad anti-O-lactamase spectrum, ranging from the plasmid-mediated TEM-1 SHV-1 enzyme to the highly potent chromosomally mediated enzyme produced by Bacteroides species. Sulbactam is also active against some of the fixed, nontransferable chromosomally mediated enzymes produced by gram-negative bacteria, but this activity is much less predictable than the activity against plasmid-mediated transferable enzymes.
Sulbactam, like other /3-lactamase inhibitors, has limited direct antimicrobial activity. A notable exception, however, is its high level of activity against Bacteroides fragilis and Acinetobacter species, organisms against which most cephalosporins display little or no activity. In addition, sulbactam potentiates the bactericidal activity of 0-lactam antibiotics against gramnegative bacterial strains by attacking the penicillin-binding protein (PBP) 2 of these pathogens. Since the bactericidal action of most cephalosporins and penicillins is accomplished by attacking PBP1 and PBP3, the additional effect of sulbactam In Vitro Activity of Cefoperazone Alone Table 2 depicts the in vitro activity of cefoperazone against non-(3-lactamase-producing organisms. When unaffected by 0-lactamases, the in vitro activity of cefoperazone is high, as evidenced by its low MICs for a wide variety of gram-positive and gram-negative organisms. When a /3-lactamase is present, the MIC of cefoperazone is increased. For example, table 3 shows that the MICs of cefoperazone for non-enzyme-producing strains of H. influenzae and N. gonorrhoeae were 0.06 mg/L and 0.001 mg/L, respectively, and that the MICs of cefoperazone for 0-lactamase -producing strains of H. influenzae and N. gonorrhoeae increased to 0.25-0.5 mg/L and 0.5 mg/L, respectively. When no enzyme is present, cefoperazone displays excellent activity against Enterobacteriaceae including E. coli and species of Klebsiella, Enterobacter, and Proteus, as well as P. aeruginosa. However, 0-lactamases can be pro- duced by all these species. If a transferable enzyme is present, /3-lactamases are generally produced at high levels. The clinical significance of chromosomally mediated [3-lactamases depends on whether there is partial or full expression of these enzymes or if the enzymes are being produced only at a basal level. When there is only basal expression of chromosomally mediated class I enzymes, there may be an increase in MICs, but values usually remain in the therapeutic range. However, in the presence of full derepression of those enzymes (such as can occur by selection of mutants during treatment), the MICs of cefoperazone are increased above the therapeutic levels. Table 4 depicts the changes in in vitro activity that can be expected when sulbactam is combined with cefoperazone. Essentially, cefoperazone's full spectrum of activity is restored against ,3-lactamase-producing strains, and penicillin-resistant S. aureus isolates become susceptible, as do the array of gram-negative organisms that produce transferable /3-lactamases. Some organisms that produce chromosomally mediated enzymes such as Pseudomonas also become susceptible. Sulbactam is also active against species of Acinetobacter and Bacteroides.
In Vitro Activity of Sulbactam/Cefoperazone
Changes in the susceptibility of various organisms to cefoperazone have been illustrated in greater detail in a study by Fass et al. [7] . Table 5 shows the percentage of bacterial strains for which MIC values became significantly lower when sulbactam was added to cefoperazone. As can be seen, substantially lower MICs were observed for 99% of Acinetobacter calcoaceticus strains, 81% of E. coli strains, and 75% of Proteus species strains; thus, most of these isolates were determined to be within the therapeutic range of cefoperazone. Table 5 also shows the actual mean MIC values of cefoperazone and cefoperazone/sulbactam for these organisms. The higher the prevalence of the /3-lactamases, the greater the benefit of adding sulbactam to the drug regimen.
Conclusion
The combination of sulbactam and the third-generation cephalosporin cefoperazone represents a logical new approach to the widespread problem of antibiotic resistance due to 0-lactamase -producing pathogens. Sulbactam/cefoperazone is effective against /3-lactamase -producing strains of gram-positive staphylococci as well as the numerous plasmid-mediated /3-lactamases produced by gram-negative organisms. This combination is active against some of the chromosomally mediated enzymes. In addition, cefoperazone's spectrum of activity is extended as a result of sulbactam's activity against Bacteroides and Acinetobacter isolates. * A few strains of these species may have abnormal penicillin-binding proteins or a barrier resistance preventing access of the antibiotics. NOTE. Data are from [7] . * This figure is related to the prevalence of 0-lactamases within this group of bacteria; there is a high prevalence of transferable enzymes in the E. coli isolates (and therefore a large mean reduction in the MIC of cefoperazone) and a much lower prevalence of transferable enzymes in the P. aeruginosa isolates.
Because of this broad, potent spectrum of activity, the combination of sulbactam/cefoperazone should prove useful in the treatment of a variety of acute and chronic infections in hospitalized patients that are caused by both 0-lactamase-and non-O-lactamase-producing strains of bacteria, including those that cause intra-abdominal and hepatobiliary infections, gynecological and obstetrical infections, respiratory and urinary tract infections, and gram-negative septicemia. With restoration of the full therapeutic potential of cefoperazone, clinicians can be more confident of covering a significant range of common pathogenic organisms, whether or not they produce 0-lactamase.
